Table 2.

Association of OX40 expression with genetic landscape and clinical parameters

CharacteristicAnalyzed patientsP value two-sidedaCox regressionCorrelationb
PML/RARA t(15;17)96<0.05
RUNX1/RUNX1T1 t(8;21)94n.s.
CBFB/MYH11 inv(16)93n.s.
Subtype of FLT3 mutation
FLT3-ITD84<0.05
FLT3-TKD83n.s.
NPM184n.s.
CEBPA55n.s.
MLL-PTD78n.s.
ELN90n.s.
ELN 201788n.s.
Survival105n.s.
CR63n.s.
Etiology108n.s.
pAML87
sAML14
tAML7
Relapsen.s.
FAB105n.s.
Age at diagnosis110n.s.
Sex110n.s.
PBB (%)109n.s.
WBC108n.s
Plt (G/L)108n.s.
HB (g/dL)108n.s.
CRP (mg/dL)108n.s.
  • Abbreviations: ELN, European LeukemiaNet classification; ELN 2017, modified European LeukimiaNet classification; CR, complete remission; pAML, de novo AML; tAML, therapy-related AML; sAML, secondary AML evolving from MDS/MPS; FAB, French–American–British classification; PBB, peripheral blood blasts among nucleated cells; WBC, white blood count; Plt, platelets; HB, hemoglobin; CRP, C-reactive protein; n.s., not significant.

  • aAll P values are two-sided and were calculated either with Mann–Whitney or Kruskal–Wallis test or, for categorial variables, with the χ2 tests.

  • bCorrelation Spearman r.